Xeris Biopharma Holdings
XERS
103 hedge funds and large institutions have $128M invested in Xeris Biopharma Holdings in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 15 closing their positions.
1,222% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $320K
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
23% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 26
12% more funds holding
Funds holding: 92 → 103 (+11)
7% more capital invested
Capital invested by funds: $120M → $128M (+$8.18M)
4.34% more ownership
Funds ownership: 32.91% → 37.25% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18.2M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.54M |
| 3 |
Millennium Management
New York
|
+$2.97M |
| 4 |
Goldman Sachs
New York
|
+$1.22M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$2.98M |
| 2 |
Morgan Stanley
New York
|
-$2.96M |
| 3 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$1M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1M |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$663K |
XERS Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2022, worth a combined $128M — up 6.8% from $120M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new XERS positions and 15 closed out — a net gain of 12 holders — while 32 added to existing stakes and 26 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $18.2M. The largest seller was Man Group, cutting an estimated $2.98M.
- 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2022, up from 92 in Q4 2021.
- Funds reported $128M of Xeris Biopharma Holdings stock for Q1 2022, up 6.8% quarter-over-quarter.
- 27 funds opened new Xeris Biopharma Holdings positions in Q1 2022 and 15 closed out, a net change of +12 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2022 was Armistice Capital, an estimated $18.2M added.
- The largest Xeris Biopharma Holdings seller in Q1 2022 was Man Group, an estimated $2.98M sold.
Based on aggregated 13F filings for Q1 2022.